Add like
Add dislike
Add to saved papers

Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study.

Secukinumab is an interleukin (IL)-17A antagonist approved in 2015 by health agencies around the world for the treatment of moderate to severe plaque psoriasis in adult patients. Current knowledge of the efficacy and safety of secukinumab is limited to data from phase III randomized controlled trials (RCT). Despite the acceptable safety profile and promising efficacy results, there remains to be a lack of understanding of treatment outcomes in real-world clinical practice. This article is protected by copyright. All rights reserved.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app